HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...
Drug-resistance amino acids known in HIV-1 [36] are shown in bold. Amino acids that are the same as those of the reference HIV-1 HXB2 are shown as bars. † Consensus amino acid sequences were prepared ...
The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step ...
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are a class of antiretroviral drugs that help manage HIV by blocking a key enzyme the virus needs to replicate its RNA into DNA. There ...
Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...
New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.
Bacteria defend themselves from viral infection using diverse immune systems, many of which sense and target foreign nucleic acids. Defense-associated reverse transcriptase (DRT) systems provide an ...
On the third day of the J.P. Morgan Healthcare Conference, Arbor Biotechnologies and Vertex Pharmaceuticals announced that they would be expanding into reverse transcription-based in vivo genetic ...
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...
REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results